LY6G6C is a lymphocyte antigen 6 superfamily member that functions as a GPI-anchored cell surface immunoregulatory protein 1. The protein is highly expressed at the leading edges of cells on filopodia, structures involved in cell adhesion and migration 1. Functionally, LY6G6C is glycosylated and can form part of larger protein complexes 1, with potential ligands expressed on hematopoietic cell lines, suggesting a role in cell differentiation 1. Disease relevance: LY6G6C has been identified as an independent prognostic risk factor for colorectal cancer, contributing to machine learning-based survival prediction systems 2. It is also implicated in susceptibility to HIV-related Kaposi's sarcoma through a class III MHC haplotype 3, and genome-wide association studies identified LY6G6C as a susceptibility gene for coronary artery disease with significantly altered expression between patients and controls 4. Additionally, LY6G6C upregulation may serve as a protective biomarker for radiation-induced oral mucositis 5, and it is part of an interferon-responsive gene panel involved in gut microbiota regulation 6. These findings suggest LY6G6C plays multifaceted roles in immune regulation, cell-cell interactions, and disease pathogenesis across multiple conditions.